A Phase I clinical and pharmacological study of cis-diamminedichloro(2-methylpyridine) platinum II (AMD473)

AMD473 is a novel sterically hindered platinum cytotoxic with demonstrated ability to overcome acquired resistance to cisplatin in vitro and in human tumour xenografts. A single-agent dose escalating Phase I study was performed. AMD473 was initially administered intravenously as a 1 h infusion every...

Descripción completa

Detalles Bibliográficos
Autores principales: Beale, P, Judson, I, O'Donnell, A, Trigo, J, Rees, C, Raynaud, F, Turner, A, Simmons, L, Etterley, L
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376375/
https://www.ncbi.nlm.nih.gov/pubmed/12671715
http://dx.doi.org/10.1038/sj.bjc.6600854

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376375/
https://www.ncbi.nlm.nih.gov/pubmed/12671715
http://dx.doi.org/10.1038/sj.bjc.6600854

Ejemplares similares